BCL2 and colorectal carcinoma: To explore the above confirmed ability of DR_MOMP to predict responses to BCL-2 antagonists in a pre-clinical in vivo setting, we first profiled BCL-2 proteins in several metastatic CRC PDX tissue samples that were all originally derived from metastatic (m)CRC patient liver metastases, established by Bertotti et al. [12,13].